Novo Nordisk A/S Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 54 trades in Novo Nordisk A/S (NYSE: NVO) since 2015, across 16 members, worth an estimated $1.8M in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 29 buys against 25 sells, a modestly buy-led skew, with Democratic members responsible for 31% of the trades and Republican members 69%. The most recent disclosure shown was filed April 2026, and Lisa Mcclain has filed the most NVO transactions among those shown, with 7. Other recent filers include Ro Khanna, Marjorie Taylor Greene, and Scott Scott Franklin. One notable disclosed move was a sale by Michael T. McCaul on June 16, 2025, down 42.8% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Novo Nordisk A/S (NVO) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Novo Nordisk A/S congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | |
|---|---|---|---|---|---|---|---|
 Ro Khanna House | Apr 7, 2026 | Mar 13, 2026 | 25 days | BUY |  $1,001 - $15,000 | +14.70% | |
Ro Khanna House | Mar 9, 2026 | Feb 13, 2026 | 24 days | BUY | $1,001 - $15,000 | -12.16% | |
 Lisa Mcclain House | Nov 21, 2025 | Oct 31, 2025 | 21 days | SELL | $1,001 - $15,000 | -11.97% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | SELL | $1,001 - $15,000 | -12.99% | |
Lisa Mcclain House | Nov 21, 2025 | Oct 30, 2025 | 22 days | BUY | $1,001 - $15,000 | -12.99% | |
| Oct 20, 2025 | Oct 15, 2025 | 5 days | BUY | $1,001 - $15,000 | -23.24% | ||
Lisa Mcclain House | Oct 22, 2025 | Sep 11, 2025 | 41 days | BUY | $1,001 - $15,000 | -19.82% | |
| Aug 29, 2025 | Aug 28, 2025 | 1 day | BUY | $1,001 - $15,000 | -22.40% | ||
| Aug 20, 2025 | Aug 19, 2025 | 1 day | BUY | $15,001 - $50,000 | -20.52% | ||
 Scott Scott Franklin House | Aug 14, 2025 | Aug 4, 2025 | 10 days | BUY | $1,001 - $15,000 | -9.79% |
Novo Nordisk A/S (NVO) congressional trading FAQ
Can members of Congress legally trade Novo Nordisk A/S (NVO) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Novo Nordisk A/S (NVO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; it does not imply any trade was improper.
Are congressional Novo Nordisk A/S (NVO) trades public?
Yes. Every congressional trade in Novo Nordisk A/S (NVO) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Novo Nordisk A/S (NVO)?
Members of Congress have disclosed 54 trades in Novo Nordisk A/S (NVO) worth $1.8M across 16 members, according to public STOCK Act filings.
Which members of Congress have traded Novo Nordisk A/S (NVO)?
Recent and active filers of Novo Nordisk A/S (NVO) disclosures include Lisa Mcclain, Michael T. McCaul, Marjorie Taylor Greene. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Novo Nordisk A/S (NVO) more?
Across disclosed Novo Nordisk A/S (NVO) trades, 31% were by Democrats and 69% by Republicans, led by Republicans (69%).
What is the most recent congressional Novo Nordisk A/S (NVO) trade?
The most recent disclosed Novo Nordisk A/S (NVO) trade was a purchase by Ro Khanna, filed Apr 6, 2026.
Browse all stocks Congress tradesCongressional trading overviewNovo Nordisk A/S (NVO) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.